实验研究
ENGLISH ABSTRACT
Rho激酶抑制剂盐酸法舒地尔对人LECs增生、迁移及ECM合成的抑制作用
任师杰
张凤妍
祁颖
崔琨明
作者及单位信息
·
DOI: 10.3760/cma.j.issn.2095-0160.2015.04.005
Inhibition of Rho-kinase inhibitor fasudil on the growth and migration of human LECs and extracellular matrix synthesis
Ren Shijie
Zhang Fengyan
Qi Ying
Cui Kunming
Authors Info & Affiliations
Ren Shijie
Department of Ophthalmology, Affiliated First Hospital of Zhengzhou University, Zhengzhou 450052, China
Zhang Fengyan
Qi Ying
Cui Kunming
·
DOI: 10.3760/cma.j.issn.2095-0160.2015.04.005
218
19
0
0
0
0
PDF下载
APP内阅读
摘要

背景白内障囊外摘出术后晶状体囊残留的晶状体上皮细胞(LECs)的生物学行为改变是后发性白内障的主要病理改变。Rho激酶抑制剂盐酸法舒地尔具有抑制细胞骨架的重构、迁移、黏附及纤维化等作用,但对LECs的作用尚不清楚。

目的探讨盐酸法舒地尔对人LECs株HLEB-3细胞增生、迁移的作用及其对细胞外基质(ECM)合成的影响。

方法常规培养HLEB-3细胞,对照组细胞仍进行常规培养,药物组培养液中加入不同浓度的盐酸法舒地尔,使其终浓度分别为10、20、40和60 μmol/L,分别于培养后12、24和48 h采用细胞计数试剂盒8(CCK-8)法检测各组细胞的增生情况,计算不同剂量盐酸法舒地尔对细胞增生的抑制率;分别于处理后12、24、36和48h采用Transwell小室迁移实验检测各组的迁移细胞数;并于上述时间点采用ELISA法检测各组细胞上清中Ⅰ型胶原(COL-Ⅰ)、纤维连接蛋白(FN)的质量浓度及细胞内α-平滑肌肌动蛋白(α-SMA)质量浓度,对各组间的检测结果进行比较。

结果不同浓度盐酸法舒地尔组HLEB-3细胞增生抑制率均明显高于对照组,随着盐酸法舒地尔浓度的增加,HLEB-3细胞增生抑制率明显增加,组间总体差异有统计学意义( F 浓度=966.727, P=0.000);随着盐酸法舒地尔作用时间的延长,HLEB-3细胞增生抑制率明显增加,总体比较差异有统计学意义( F 时间=280.428, P=0.000)。Transwell小室迁移实验显示,实验后48 h,对照组穿过聚碳酸酯膜的细胞数为(29.20±1.28)个,10、20、40和60 μmol/L盐酸法舒地尔组迁移的细胞数分别为(24.40±1.33)、(17.00±1.10)、(14.60±0.68)和(6.60±1.29)个,随着盐酸法舒地尔浓度的增加,HLEB-3细胞的迁移数逐渐减少,差异有统计学意义( F=57.34, P<0.05).随着盐酸法舒地尔浓度的增加和作用时间的延长,细胞上清液中COL-Ⅰ和FN质量浓度逐渐降低,差异均有统计学意义(COL-Ⅰ: F 浓度=143.992, P=0.000; F 时间=113.745, P=0.000.FN: F 浓度=81.761, P=0.000; F 时间=69.602, P=0.000);细胞内α-SMA质量浓度逐渐下降,差异均有统计学意义( F 浓度=78.156, P=0.000; F 时间=65.162, P=0.000)。

结论盐酸法舒地尔可抑制体外培养HLEB-3的增生、迁移及ECM的合成,其作用呈剂量和时间依赖性。

Rho相关激酶/拮抗剂和抑制剂;晶状体上皮细胞/药效;人;细胞迁移;细胞增生;Ⅰ型胶原;纤维连接蛋白;细胞外基质;盐酸法舒地尔/药理作用
ABSTRACT

BackgroundBiological behavior changes of human lens epithelial cells (LECs) and extracellular matrix (ECM) synthesis are major events in the pathogenesis of posterior capsule opacification (PCO). Rho-kinase inhibitor fasudil can inhibit the cytoskeleton remodeling, migration and fibrosis, however, the mechanism of its effect in LECs is below understood.

ObjectiveThis study was to investigate the role of Rho-kinase inhibitor fasudil in proliferation, migration of human LECs and ECM synthesis in vitro.

MethodsHuman LECs line HLEB-3 cells were regularly cultured and assigned to the control group and the drug treatment groups. Different doses of fasudil were added into the medium to make the final concentrations 10, 20, 40 and 60 μmol/L, respectively. Cell proliferation was assessed by cell counting kit-8 (CCK-8) assay in 12, 24 and 48 hours after addition of drug to calculate the growth inhibitory rate. Transwell test was employed to detect the migrating number of the cells in 12, 24, 36 and 48 hours after action of drug. The concentrations of collagen type Ⅰ (COL-Ⅰ), fibronectin (FN) in cell supernatant and α-smooth muscle actin (α-SMA) content in the cells were measured by ELISA.

ResultsThe cell growth inhibitory rates in different doses of fasudil groups were higher than that in the control group. The cell growth inhibitory rates were gradually elevated as the increases of fasudil concentrations and prolong of action time ( F concentration=966.727, P=0.000; F time=280.428, P=0.000). Transwell migration assay showed that the number of migration cells across polycarbonate membrane was 29.20±1.28 in the control group after 48 hours of incubation, which was much more than 24.40±1.33, 17.00±1.10, 14.60±0.68, 6.60±1.29 in the 10, 20, 40 and 60 μmol/L fasudil groups, respectively, with a significant difference among the five groups ( F=57.34, P<0.05). COL-Ⅰ and FN protein contents in supernatant were gradually declined with the increase of drug concentrations and lapse of time (COL-Ⅰ: F concentration=143.992, P=0.000; F time=113.745, P=0.000.FN: F concentration=81.761, P=0.000; F time=69.602, P=0.000), and the α-SMA levels in the cells were significantly reduced with the increase of drug concentrations and lapse of time ( F concentration=78.156, P=0.000; F time=65.162, P=0.000).

ConclusionsFasudil can inhibit the proliferation, migration and ECM synthesis of human LECs in vitro in a dose- and time-dependent manner.

Rho-associated kinases/antagonists and inhibitors;Epithelial cells, lens/drug effect;Humans;Cell migration;Cell proliferation;Collagen type I;Fibronectins;Extracellular matrix;Fasudil /pharmacology
Zhang Fengyan, Email: mocdef.nabuyilaxnaygnefgnahz
引用本文

任师杰,张凤妍,祁颖,等. Rho激酶抑制剂盐酸法舒地尔对人LECs增生、迁移及ECM合成的抑制作用[J]. 中华实验眼科杂志,2015,33(4):311-315.

DOI:10.3760/cma.j.issn.2095-0160.2015.04.005

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
白内障囊外摘出术后晶状体囊残留的晶状体上皮细胞(lens epithelial cells,LECs)发生增生、迁移、胶原沉积以及晶状体纤维再生可导致后囊膜混浊(posterior capsular opacification, PCO),即后发性白内障。研究表明,成人白内障术后5年内约有43%的患者发生PCO而导致视力再度下降 [ 1 , 2 , 3 ]。Rho为Ras同源物,是肌动蛋白细胞骨架重新组装过程中的主要调节因子之一,可激活下游的关键靶效应分子ROCK,从而调节LECs的多种生物学行为 [ 4 ]。盐酸法舒地尔是目前在临床上及实验中常用的Rho/ROCK信号通路选择性抑制剂,可降低细胞内肌球蛋白轻链的磷酸化水平,从而抑制细胞骨架的重装 [ 5 , 6 ]。关于盐酸法舒地尔对LECs的作用机制目前报道尚少。观察盐酸法舒地尔对人LECs增生、迁移的作用及其对细胞外基质(extracellular matrix, ECM)的影响,为探讨盐酸法舒地尔是否有助于PCO的防治提供实验依据。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Awasthi N , Guo S , Wagner BJ . Posterior capsular opacification: a problem reduced but not yet eradicated[J]. Arch Ophthalmol, 2009,127(8):555562. doi: 10.1001/archophthalmol.2009.3 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
崔琨明,张凤妍,祁颖,. 灯盏花素对转化生长因子-β 2诱导的人晶状体上皮细胞上皮-间质转化的影响 [J]. 中华实验眼科杂志, 2013,31(10):930934. doi: 10.3760/cma.j.issn.2095-0160.2013.10.006 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Chong CC , Stump RJ , Lovicu FJ ,et al. TGFbeta promotes Wnt expression during cataract development[J]. Exp Eye Res, 2009,88(2):307313. doi: 10.1016/j.exer.2008.07.018 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Lee J , Moon HJ , Lee JM ,et al. Smad3 regulates Rho signaling via NET1 in the transforming growth factor-β-induced epithelial-mesenchymal transition of human retinal pigment epithelial cells[J]. Biol Chem, 2010,285(34):2661826627. doi: 10.1074/jbc.M109.073155 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Li F , Xia W , Li A ,et al. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats[J]. Pharmacol Res, 2007,55(1):6471. doi: 10.1016/j.phrs.2006.10.009 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Jaffe AB , Hall A . Rho GTPases: biochemistry and biology[J]. Anna Rev Cell Dev Biol, 2005,21(3):247269. doi: 10.1146/annurev.cellbio.21.020604.150721 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Chong CC , Stump RJ , Lovicu FJ ,et al. TGFbeta promotes Wnt expression during cataract development[J]. Exp Eye Res, 2009,88(2):307313. doi: 10.1016/j.exer.2008.07.018 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Rao V , Wawrousek E , Tamm ER ,et al. Rho GTPase inactivation impairs lens growth and integrity[J]. Lab Invest, 2002,82(2):231239. doi: 10.1038/labinvest.3780415 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Saika S . Relationship between posterior capsule opacification and intraocular lens biocompatibility[J]. Prog Retin Eye Res, 2004,23(3):283305. doi: 10.1016/j.preteyeres.2004.02.004 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Hein TW , Rosa RH Jr, Yuan Z . Divergent roles of nitric oxide and rho kinase in vasomotor regulation of human retinal arterioles[J]. Invest Ophthalmol Vis Sci, 2010,51(3):15831590. doi: 10.1167/iovs.09-4391 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Del Re DP , Miyamoto S , Brown JH ,et al. RhoA/Rho kinase upregulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis[J]. J Biol Chem, 2007,282(11):80698078. doi: 10.1074/jbc.M604298200 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Sahai E , Marshall CJ . Rho-GTPases and cancer[J]. Nat Rev Cancer, 2002,2(2):133142. doi: 10.1038/nrc725 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Rattan R , Giri S , Singh AK ,et al. Rho/ROCK pathway as a target of tumor therapy[J]. Neurosci Res, 2006,83(2):243255. doi: 10.1002/jnr.20707 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
张凤妍,Email: mocdef.nabuyilaxnaygnefgnahz
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号